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Research Article
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Abstract
Background: Anticholinergic and sedative medications are frequently prescribed to older individuals. These medications are associated with 
short-term cognitive and physical impairment, but less is known about long-term associations. We therefore examined whether over 20 years 
cumulative exposure to these medications was related to poorer cognitive and physical functioning.
Methods: Older adult participants of the Longitudinal Aging Study Amsterdam (LASA) were followed from 1992 to 2012. On seven 
measurement occasions, cumulative exposure to anticholinergic and sedative medications was quantified with the drug burden index (DBI), a 
linear additive pharmacological dose–response model. Cognitive functioning was assessed with the Mini-Mental State Examination (MMSE), 
Alphabet Coding Task (ACT, three trials), Auditory Verbal Learning Test (AVLT, learning and retention condition), and Raven Colored 
Progressive Matrices (RCPM, two trials). Physical functioning was assessed with the Walking Test (WT), Cardigan Test (CT), Chair Stands 
Test (CST), Balance Test (BT), and self-reported Functional Independence (FI). Data were analyzed with linear mixed models adjusted for age, 
education, sex, living with a partner, BMI, depressive symptoms, comorbidities (cardiovascular disease, diabetes, cancer, COPD, osteoarthritis, 
CNS diseases), and prescribed medications.
Results: Longitudinal associations were found of the DBI with poorer cognitive functioning (less items correct on the three ACT trials, AVLT learning 
condition, and the two RCPM trials) and with poorer physical functioning (longer completion time on the CT, CST, and lower self-reported FI).
Conclusions: This longitudinal analysis of data collected over 20 years, showed that higher long-term cumulative exposure to anticholinergic 
and sedative medications was associated with poorer cognitive and physical functioning.
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Polypharmacy (ie, the prescribing of ≥5 medications) is a prevalent 
condition in older people (1,2) that increases the risk of adverse drug 
effects and consequences. Particularly harmful are medications with 
anticholinergic and sedative properties, which are prescribed to up 
to a quarter of older persons (3,4). These medications have been 
associated with poorer cognitive functioning (5–9), poorer physi-
cal functioning (5,9,10), and increased risk of hip fractures (11). 
Anticholinergic medications exert central antagonistic effects on 
muscarinic receptors thereby inhibiting acetylcholine transmission 
within hippocampal, fusiform, inferior prefrontal cortical, and stri-
atal areas (12–14). Sedative medications from the group of benzodi-
azepines increase the inhibitory effects of GABAergic neurons (15). 
Anticholinergic and sedative medications exert peripheral antagonis-
tic effects as well. Anticholinergic medications inhibit acetylcholine-
mediated muscle contractions and glandular secretion, leading to 
constipation and dry mouth (12). Sedative medications are known 
to impair neuromuscular processing important for maintaining bal-
ance (16) and to impair muscle strength (17). Various medications 
including those for the alimentary and respiratory tracts, as well as 
psychotropic, cardiovascular and pain medications have anticholin-
ergic and/or sedative properties.
Given the prevalence of cognitive and physical impairment as 
well as polypharmacy and the frequent prescribing of anticholinergic 
and sedative medications in older people, it is important to assess 
the associations of prolonged cumulative exposure to anticholinergic 
and sedative medications with cognitive and physical functioning. 
However, the majority of studies that examined these associations 
had a short to medium follow-up duration (6,18–20) while relatively 
few studies had a longer follow-up duration (21,22).
Less is therefore known about prolonged exposure to anticho-
linergic and sedative medications. Extrapolations of short- to 
medium-term findings to the long term are not necessarily valid. 
Although anticholinergic exposure was indeed found to exert 
potentially irreversible brain atrophy (23), tolerance to these medi-
cations is also known to occur and could actually reduce adverse 
effects over time (13).
In the present study, we therefore examined older individu-
als’ cumulative exposure to anticholinergic and sedative medica-
tions over up to 20 years. Exposure was quantified with the drug 
burden index (DBI) (24), which is a linear additive pharmacologi-
cal dose–response model. The DBI summates the standardized doses 
of anticholinergic and sedative medications into an overall value of 
exposure (see Cumulative Exposure to Anticholinergic and Sedative 
Medications section). The DBI is based on patients’ medication pre-
scriptions and does not require blood withdrawal. It is therefore 
noninvasive and feasible for large-scale routine use.
Accordingly, we examined whether prolonged cumulative expo-
sure to anticholinergic and sedative medications over up to 20 
years was associated with poorer cognitive and physical functioning 
in older community-dwelling individuals.
Methods
Participants and Study Design
The Longitudinal Aging Study Amsterdam (LASA study) is a Dutch 
nationally representative prospective cohort study of community-
dwelling older adults. Participants were aged 55–85 years at base-
line in 1992/1993. The primary aims of the LASA study have been 
to investigate the determinants, trajectories, and consequences of 
physical, cognitive, emotional, and social functioning in older adults 
(25). The sample was recruited from registries of 11 municipali-
ties in three geographic regions in The Netherlands. Older people 
and men were oversampled to anticipate differential attrition with 
regard to age and sex. Data have been collected since the baseline 
measurement at follow-up measurement occasions separated by 
3-year intervals. For the present analyses, we used the data from 
20 years collected at 7 measurement occasions until 2011/2012 (25). 
Data were collected by trained interviewers in participants’ homes 
through a main interview lasting on average 1 hour and 45 minutes, 
a self-report questionnaire, and an additional medical interview. All 
participants gave informed consent and the medical ethical commit-
tee of the VU Medical Center approved the study. For the present 
analyses, we excluded participants with potential drinking problems 
in the past and present (ie, ≥6 glasses of alcohol at least once a week 
or 21 days per month drinking ≥4 glasses), and those who reported 
to have severe hearing and vision problems. This was done, because 
excessive alcohol consumption and sensory deficits are likely to 
bias performance on tests of cognitive and physical functioning (see 
Outcomes section).
Cumulative Exposure to Anticholinergic and 
Sedative Medications
As part of the medical interview conducted at each measurement 
occasion, participants were asked to show their medication contain-
ers. The name, dose, frequency of intake, and duration of use of 
every medication was recorded on a standardized form. All medica-
tions were recoded into the codes of the Anatomical Therapeutic 
Chemical (ATC) classification system (26). Missing doses were 
imputed by mean doses in the study population. At each measure-
ment occasion, we calculated cumulative exposure to anticholinergic 




where D stands for the prescribed daily dose of an individual medi-
cation and δ represents the minimum daily oral dose according to 
Dutch prescribing guidelines (24). In a systematic manner, we pre-
viously compiled a list of medications with anticholinergic and/or 
sedative potency (27). Only medications for which a dose could be 
determined were considered. Therefore, only medications that were 
prescribed regularly by a physician at the time of the examination 
were included, while medications taken “pro re nata” were excluded 
from the DBI calculation.
Outcomes
In conjunction with measuring global cognitive functioning with 
the Mini-Mental State Examination (28) (max. 30 points), cognitive 
functioning in the following specific domains (neuropsychological 
tests) were collected: selective and sustained attention [Alphabet 
Coding Task, number of correct responses on three trials of 1 minute 
(29)], learning [Auditory Verbal Learning Test, three learning trials 
(30)], episodic memory [Auditory Verbal Learning Test, retention 
condition (30)] and fluid intelligence [Raven Colored Progressive 
Matrices, subset A  and B, 24 items (31)]. Outcomes of physical 
functioning were time (in seconds) to perform validated objective 
function tests (32) of lower extremities (Chair Stands Test, Walking 
Test, Balance Test) and upper extremities (Cardigan Test). In add-
ition, participants rated their functional independence in daily life 
on a self-reported measure (Functional Independence Scale, 6 items 
on a 4-point scale). Outcomes were assessed on all measurement 
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occasions except for the Raven Colored Progressive Matrices which 
were not assessed at the seventh measurement occasion (2011–
2012), and the Balance Test and the Functional Independence Scale 
which were not assessed at the first measurement occasion (1992–
1993). See Supplementary Appendix 1 for a further description of 
these outcomes.
Covariates
We assessed time independent and time dependent covariates. Time 
independent covariates included sex and education (years). Time 
dependent covariates included age, living with a partner (no/yes), 
BMI, depressive symptoms, number of comorbidities, and pre-
scribed medications. Depressive symptoms were measured with the 
Center for Epidemiologic Studies Depression (CES-D) scale. The 
CES-D scale consists of 20 items with 4-point scales ranging from 
0 “rarely or never” to 3 “mostly or always.” Its score ranges from 
0 to 60, with higher scores indicating more depressive symptoms 
(33). Comorbidities included the most prevalent comorbidities in the 
Netherlands in people aged 55 years and older. These were heart dis-
ease (myocardial infarction, angina pectoris, coronary artery disease, 
congestive heart failure, and arrhythmias), diabetes, peripheral vas-
cular disease, stroke, cancer, chronic obstructive pulmonary disease 
and asthma, osteoarthritis, and nervous system diseases (including 
Parkinson’s disease).
Statistical Analysis
Participants’ background characteristics were summarized with 
descriptive statistics. In line with previous studies, we compared 
participants who had no anticholinergic and sedative exposure 
(DBI = 0) with those who had medium exposure (0 < DBI < 1), and 
high exposure (DBI ≥ 1) on baseline characteristics. We also exam-
ined Spearman’s rank correlations between measures of cognitive and 
physical functioning with participants’ characteristics. Differential 
attrition was examined by studying if participants’ baseline charac-
teristics predicted their completion of the final follow-up measure-
ment occasion using multivariable logistic regression analysis.
Outliers or values >99th percentile on the outcome variables of 
cognitive and physical functioning were replaced by the value of the 
99th percentile of each variable. Owing to skewed distributions, the 
Walking Test, Cardigan Test, the MMSE and the Raven Colored 
Progressive Matrices variables were log-transformed, while the 
Balance Test was dichotomized. Missing values were imputed. For 
the DBI and number of comorbidities, missing values were assumed 
to reflect absence and coded as zero. Multiple imputation was per-
formed for missing values of education (years), CES-D, and BMI. 
Imputed values were obtained in three rounds and missing values 
were then replaced by the mean value of these three imputations. 
Missing values on outcomes of cognitive and physical functioning 
were not imputed.
In multivariable linear mixed models, we examined longitudinal 
relationships between cumulative anticholinergic and sedative expo-
sure measured with the DBI (independent variable) and outcomes of 
cognitive and physical functioning (dependent variables). To account 
for dependence of repeated measurements within participants, these 
models included a random intercept and random slope at the partici-
pant level. Thereby, these models allow time-series to vary between 
individuals. Linear mixed models also allow for a different number 
of repeated measures per participant and are appropriate for dealing 
with missing data in the repeatedly measured outcome variables. The 
DBI categories of no, medium, and high exposure were represented 
by dummy variables. Analyses were adjusted for sex, education 
(years), age, living with a partner, BMI, depressive symptoms, num-
ber of comorbidities, and prescribed medications. However, to antic-
ipate collinearity, adjustment was not made for the total number of 
medications but rather for the number of medications excluded from 
the DBI calculation.
In a sensitivity analysis, we calculated a DBI for anticholiner-
gic and sedative medications that had been prescribed for at least 
≥1 year(s) before each measurement occasion and we repeated the 
main analyses. For all parameters, we calculated 95% confidence 
intervals (95% CIs) and p values. Data transformation and imputa-
tion of missing values, descriptive analyses, and differential attrition 
analyses were done with SPSS Statistics for Windows, version 24.0 
(IBM). Linear mixed models were conducted with MLwiN, version 
2.32 (Centre for Multilevel Modelling, University of Bristol, UK).
Results
Of the 3,107 individuals who consented to participate, 291 were 
excluded because they had no medication use reported and 189 
were excluded for other reasons, leaving 2,627 participants eligible 
at baseline. A total of 2,252 participants completed the first follow-
up and 726 completed the final sixth follow-up 20 years later (Figure 
1). Baseline demographic and clinical characteristics are presented in 
Table 1. Of the eligible participants, 52% (N = 1,378) were women 
and 64% (N = 1,686) were living with a partner. On average, they 
were 70.3 (±8.7) years, had received 8.8 (±3.3) years of educa-
tion, 24% (N = 627) reported to have ≥2 comorbidities, and 31% 
(N = 815) were prescribed ≥3 medications.
Of the eligible participants, 75% (N = 1,974) had no exposure, 
19% (N = 493) had medium exposure and 6% (N = 160) had high 
cumulative exposure to anticholinergic and sedative medications as 
measured with the DBI at baseline. On subsequent follow-up meas-
urement occasions, percentages of participants with no exposure 
ranged from 68% to 78%, with medium exposure from 15% to 
22% and with high cumulative exposure from 6% to 12%.
Figure 1. Flowchart of inclusion of participants.









roningen user on 14 February 2020
Multivariable logistic regression analysis demonstrated that the 
baseline characteristics age (odds ratio [OR]: 1.16, 95% CI: 1.15–
1.18), depressive symptoms (OR: 1.02, 95% CI: 1.00–1.03), and 
number of comorbidities (OR: 1.21, 95% CI: 1.07–1.37) were as-
sociated with an increased risk of being lost to follow-up at the final 
measurement occasion, whereas the characteristics female sex (OR: 
Table 1. Characteristics of Study Participants
Characteristics 
All Participants
Participation at Final Measurement Occasion
Yes No
N Statistic N Statistic N Statistic
Demographic/lifestyle
N (%) sex 2,627 726 1,901
 Men  1,249 (48)  280 (39)  969 (51)
 Women  1,378 (52)  446 (61)  932 (49)
M (SD) age (years) 2,627 70.3 (8.7) 726 63.5 (6.0) 1,901 72.9 (8.1)
M (SD) education (years) 2,620 8.8 (3.3) 726 9.4 (3.3) 1,901 8.6 (3.3)
N (%) living with partner 2,627  726  1,901  
 No  941 (36)  175 (24)  766 (40)
 Yes  1,686 (64)  551 (76)  1135 (60)
M (SD) baseline BMI 2,383 26.8 (4.1) 726 26.6 (3.7) 1,901 27.0 (4.0)
Median (IQR) depressive symptomsa 2,598 6 (2–11) 726 6.5 (7.0) 1,901 8.2 (7.8)
Comorbidities
N (%) comorbidities 2,627  726  1,901  
 0  1,058 (40)  380 (52)  678 (36)
 1  942 (36)  243 (34)  699 (37)
 ≥2  627 (24)  103 (14)  524 (28)
N (%) prescribed medications 2,627  726  1,901  
 0  896 (34)  340 (47)  556 (29)
 1  524 (20)  164 (23)  360 (19)
 2  392 (15)  84 (12)  308 (16)
 ≥3  815 (31)  138 (19)  677 (36)
N (%) number prescribed non-DBI medications 2627  726  1901  
 0  1,341 (51)  464 (64)  877 (46)
 1  605 (23)  151 (21)  454 (24)
 2  405 (15)  76 (11)  329 (17)
 ≥3  276 (11)  35 (5)  241 (13)
N (%) DBI 2,627  726  1,901  
 None (0)  1,974 (75)  613 (84)  1,361(72)
 Medium (0–1)  493 (19)  99 (14)  394 (21)
 High (≥1)  160 (6)  14 (2)  146 (8)
Cognitive functioning
Median (IQR) MMSE scoreb,§ 2,616 28 (26–29) 724 28 (27–29) 1,892 27 (25–29)
M (SD) Alphabet Coding Taskc,§
 Trial 1 2,400 22.3 (7.7) 678 26.3 (6.6) 1,722 20.7 (7.5)
 Trial 2 2,392 24.4 (7.8) 677 28.4 (6.6) 1,715 22.8 (7.7)
 Trial 3 2,387 25.4 (7.8) 676 29.6 (6.4) 1,711 23.8 (7.7)
M (SD) AVLT
 Word learningd,§ 2,425 7.9 (2.5) 682 9.1 (2.3) 1,743 7.4 (2.5)
 Retentione,§ 2,425 61.1 (26.1) 682 68.4 (20.4) 1,743 58.2 (27.5)
M (SD) Raven Colored Progressive Matrices§
 Set A 2,464 10.1 (1.8) 710 10.6 (1.4) 1,754 9.9 (1.9)
 Set B 2,446 7.8 (2.8) 710 9.1 (2.4) 1,736 7.3 (2.8)
Physical functioning
 M (SD) Walking Testf,† 2,440 8.2 (3.7) 707 6.9 (2.3) 1,733 8.8 (4.0)
 M (SD) Cardigan Testf,† 2,566 13.4 (6.9) 721 10.9 (4.2) 1,845 14.4 (7.5)
 Median (IQR) Chair Stands Testf,† 2,619 12 (10–15) 723 11 (9–13) 1,896 13 (11–15)
Note: Higher score indicates †: poorer functioning §: better functioning. BMI = body mass index; IQR =  interquartile range; DBI = Drug Burden Index; 
MMSE = Mini-Mental State Examination; AVLT = Auditory Verbal Learning Test.
aAs measured with the Center for Epidemiologic Studies Depression (CES-D) scale.
bMax. 30 points.
cEach trial lasting 1 min.
dMaximum score achieved on three trials.
eNumber of retained words/maximum score and expressed as a percentage.
fNumber of seconds needed for task.
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0.45, 95% CI: 0.36–0.56), years of education (OR: 0.96, 95% CI: 
0.93–0.99), and living with partner (OR: 0.77, 95% CI: 0.61–0.98) 
were associated with a decreased risk of being lost to follow-up at 
the final measurement occasion. BMI (OR: 1.03, 95% CI: 0.99–
1.05), number of medications (OR: 1.00, 95% CI: 0.99–1.00), and 
medium versus no exposure (OR: 1.07, 95% CI: 0.80–1.42) and 
high versus no exposure (OR: 1.80, 95% CI: 0.97–3.36) to anti-
cholinergic and sedative medications as measured with the DBI were 
not associated with being lost to follow-up at the final measurement 
occasion.
Of the 29,091 identified medication prescriptions, doses were 
imputed for 1,032 prescriptions (3.5%). A  total of 5,443 (19%) 
prescriptions were for an anticholinergic or sedative medication 
including cardiovascular medications (32%), psycholeptic (29%) 
and psychoanaleptic medications (8%), other medications for the 
nervous system (10%), drugs for the respiratory tract (9%), for the 
alimentary tract (7%), and for the musculo-skeletal system (3%).
At baseline, participants with medium or high cumulative expo-
sure to anticholinergic and sedative medications were slightly older, 
less often living with a partner, had more depressive symptoms, had 
more often ≥2 comorbidities and more often ≥3 non-DBI medica-
tions prescribed than those with no exposure (Table 2). Small to 
moderate associations were observed for sex, age, educational level, 
marital status, BMI, depressive symptoms, number of comorbidities, 
and non-DBI medications with measures of cognitive and physical 
functioning (Supplementary Appendix 2).
Multivariable linear mixed model analyses of data collected over 
up to 20  years demonstrated that, after adjusting for covariates, 
cumulative anticholinergic and sedative exposure was associated 
with poorer outcomes of cognitive functioning. Participants with 
medium and high exposure had poorer performance on the three 
trials of the Alphabet Coding Task, and the learning condition of the 
Auditory Verbal Learning Test. Moreover, those with high exposure 
had also poorer performance on the two trials of the Raven Colored 
Progressive Matrices. For the Alphabet Coding Task, the strengths 
of these associations (βs ranging from −0.84 to −0.94) were weaker 
than the associations between sex and these tests (βs ranging from 
1.52 to 1.92). For the Raven Colored Progressive Matrices, the 
strengths of these associations (βs ranging from 0.07 to 0.08, log-
transformed) were comparable to the associations of sex and these 
tests (βs ranging from 0.05 to −0.07, log-transformed). No associa-
tions were found with global cognitive functioning as measured with 
the MMSE and retention on the Auditory Verbal Learning Test.
Associations were also found between the DBI and poorer 
physical functioning. Participants with medium and high exposure 
had poorer performance on the Chair Stands Test than partici-
pants with no exposure. Moreover, those with high exposure had 
poorer performance on the Cardigan Test and had lower Functional 
Independence than participants with no exposure (Table 3). The 
strengths of these associations (βs  =  0.02, 0.54, and −1.17) were, 
respectively, comparable with the associations between sex and 
the Cardigan Test (β  = −0.09), Chair Stands Test, (β  = 0.41), and 
Functional Independence (β  =  −0.95). No associations were ob-
served for the Walking Test and the Balance Test. See Supplementary 
Appendix 3 for unadjusted results and results from the sensitivity 
analysis with a DBI calculated for anticholinergic and sedative medi-
cations that had been prescribed for at least ≥1 year(s).
Discussion
This longitudinal analysis of data collected over 20 years showed 
that higher long-term cumulative exposure to anticholinergic and 
sedative medications was found to be associated with poorer cog-
nitive and physical functioning. Given the follow-up period of the 
LASA study spanning two decades of late adulthood, the present 
findings are an important complement to previous findings from 
cross-sectional studies as well as longitudinal studies with shorter 
follow-ups. Extrapolations of short to medium term findings to the 
long term may not be necessarily valid. Our findings seem to be con-
sistent with the previously observed association between anticholin-
ergic exposure and potentially irreversible brain atrophy (23) while 
they do not seem to confirm tolerance to these medications and like-
wise a reduction of adverse effects over time (13).
The associations between higher cumulative exposure to anti-
cholinergic and sedative medications and poorer cognitive func-
tioning are in line with several previous findings (20,24,34) but 
inconsistent with others (6,19,22). This variability between studies 
can be attributed to differences between studies regarding use of dif-
ferent measures of cumulative drug exposure, different measures of 
physical and cognitive outcomes and the study of different popula-
tions (35). The associations with poorer physical functioning are in 
line with previous cross-sectional studies and studies with shorter 
follow-ups (5,10,24). Of note, the associations found in the pre-
sent study between the DBI and physical functioning were not only 
found on performance tests (the Walking and the Cardigan Test), 
which reflect what people can actually do, but were also found for 




Medium (0 < DBI < 1) 
(N = 493)
High (DBI ≥ 1) 
(N = 160)
N (%) female participants 1,017 (52) 275 (56) 86 (54)
M (SD) age (years) 69.3 (8.6) 72.6 (8.3) 75.2 (7.3)
M (SD) education (years) 8.9 (3.3) 8.6 (3.2) 8.1 (3.2)
N (%) living with a partner 1,323 (67) 272 (55) 91 (57)
M (SD) BMI 26.8 (3.8) 27.0 (4.3) 27.2 (4.7)
M (SD) depressive symptomsa 6.8 (6.7) 9.9 (8.9) 11.9 (9.9)
N (%) with ≥2 comorbiditiesb 358 (18) 178 (36) 91 (57)
N (%) with ≥3 non-DBI medications prescribed 130 (7) 106 (22) 40 (25)
BMI = body mass index; DBI = drug burden index.
aAs measured with the Center for Epidemiologic Studies Depression (CES-D) scale.
bIncludes chronic obstructive pulmonary disease and asthma, heart disease, diabetes, peripheral arterial disease, incontinence, rheumatoid arthritis, and cancer.
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Table 3. Twenty-Year Associations Between Cognitive and Physical Functioning and Cumulative Anticholinergic and Sedative Exposure 
(DBI) Adjusted for Covariates
Measurement Occasions (y) (M, SD) Adjusted Parameter
Outcome × DBI 92/93 95/96 98/99 01/02 05/06 08/09 11/12 (95% CI)a
N 2,627 2,252 1,891 1,566 1,182 925 726
Cognitive functioning
MMSE scoreb
 None (DBI = 0) 27.3 ± 2.6 27.1 ± 2.9 27.1 ± 3.2 26.9 ± 3.4 26.9 ± 3.2 26.8 ± 3.3 27.0 ± 3.1 Reference
 Medium (0 < DBI < 1) 26.5 ± 3.5 26.0 ± 3.9 26.4 ± 3.5 27.1 ± 2.9 26.9 ± 2.8 26.8 ± 3.0 27.1 ± 2.5 β 0.01 (−0.02; 0.04)a, †
 High (DBI ≥ 1) 25.8 ± 3.6 26.2 ± 3.3 26.3 ± 3.5 26.4 ± 3.3 26.2 ± 3.4 26.8 ± 2.6 26.0 ± 3.7 β 0.03 (−0.01; 0.08)a, †
Alphabet Coding Taskd
Trial 1
 None (DBI = 0) 23.1 ± 7.7 21.9 ± 7.3 22.4 ± 7.2 23.6 ± 7.2 23.8 ± 6.8 22.8 ± 7.4 21.9 ± 7.2 Reference
 Medium (0 < DBI < 1) 20.6 ± 7.2 19.9 ± 7.3 20.7 ± 7.2 22.1 ± 7.2 21.9 ± 6.6 21.5 ± 7.4 21.2 ± 7.1 β −0.31 (−0.58; −0.05)e,§
 High (DBI ≥ 1) 18.1 ± 6.7 18.7 ± 6.7 19.2 ± 7.3 20.2 ± 6.9 19.6 ± 7.2 20.2 ± 6.2 18.9 ± 7.1 β −0.84 (−1.25; −0.42)e,§
Trial 2
 None (DBI = 0) 25.2 ± 7.9 24.0 ± 7.6 24.3 ± 7.4 25.4 ± 7.6 25.6 ± 7.2 24.7 ± 7.5 24.2 ± 7.2 Reference
 Medium (0 < DBI < 1) 22.6 ± 7.3 21.9 ± 7.8 22.6 ± 7.4 23.8 ± 7.3 24.1 ± 7.2 23.2 ± 7.2 22.8 ± 7.9 β −0.28 (−0.55; −0.01)e,§
 High (DBI ≥ 1) 20.0 ± 7.1 20.5 ± 7.5 20.9 ± 7.1 21.6 ± 7.0 22.2 ± 7.3 22.0 ± 6.8 21.1 ± 7.6 β −0.94 (−1.34; −0.55)e,§
Trial 3
 None (DBI = 0) 26.2 ± 7.8 25.1 ± 7.7 25.4 ± 7.4 26.3 ± 7.5 26.5 ± 7.3 25.7 ± 7.3 24.9 ± 7.1 Reference
 Medium (0 < DBI < 1) 23.9 ± 7.5 22.8 ± 7.8 23.3 ± 7.7 24.7 ± 7.2 25.1 ± 7.2 24.2 ± 7.4 23.4 ± 8.1 β −0.36 (−0.63; −0.09)e,§
 High (DBI ≥ 1) 20.9 ± 7.0 21.5 ± 7.5 22.0 ± 7.2 22.6 ± 6.9 22.8 ± 7.7 23.1 ± 6.6 21.9 ± 7.7 β −0.92 (−1.31; −0.54)e,§
15 AVLT Learningf
 None (DBI = 0) 8.0 ± 2.5 8.2 ± 2.6 8.1 ± 2.7 8.8 ± 2.7 7.6 ± 2.7 7.4 ± 2.5 8.3 ± 2.8 Reference
 Medium (0 < DBI < 1) 7.6 ± 2.4 7.5 ± 2.7 7.5 ± 2.9 8.3 ± 2.7 8.1 ± 2.6 6.7 ± 2.4 8.3 ± 2.5 β −0.14 (−0.26; −0.02)§
 High (DBI ≥ 1) 6.6 ± 2.4 7.4 ± 2.7 7.5 ± 2.7 8.0 ± 2.9 6.8 ± 2.5 7.0 ± 2.3 7.7 ± 2.6 β −0.24 (−0.42; −0.07)§
15 AVLT Retentiong
 None (DBI = 0) 62.4 ± 25.3 68.2 ± 25.9 65.0 ± 26.7 69.6 ± 24.8 65.3 ± 26.0 62.8 ± 27.0 67.6 ± 27.1 Reference
 Medium (0 < DBI < 1) 57.9 ± 27.5 62.7 ± 28.6 62.4 ± 27.4 65.5 ± 26.7 67.2 ± 29.2 60.2 ± 20.9 66.1 ± 29.0 β −1.50 (−2.94; −0.06)§
 High (DBI ≥ 1) 55.4 ± 28.5 64.5 ± 27.6 59.0 ± 26.9 69.6 ± 26.9 66.1 ± 29.0 61.6 ± 27.0 67.9 ± 28.9 β −0.70 (−2.77; 1.36)§
Raven Colored Progressive Matricese
Set A
 None (DBI = 0) 10.2 ± 1.7 10.3 ± 1.7 10.2 ± 1.8 10.3 ± 1.6 10.4 ± 1.6 10.1 ± 1.6 —h Reference
 Medium (0 < DBI < 1) 9.8 ± 1.8 9.6 ± 2.0 9.7 ± 1.9 9.9 ± 1.6 10.2 ± 1.6 10.0 ± 1.9 —h β 0.03 (−0.003; 0.06)i,†
 High (DBI ≥ 1) 9.4 ± 2.1 9.4 ± 1.9 9.5 ± 1.9 9.7 ± 1.8 9.8 ± 1.7 9.7 ± 1.8 —h β 0.08 (0.03; 0.12)i,†
Set B
 None (DBI = 0) 8.0 ± 2.8 8.1 ± 2.8 8.0 ± 2.8 8.1 ± 2.7 8.1 ± 2.6 8.1 ± 2.5 —h Reference
 Medium (0 < DBI < 1) 7.3 ± 2.8 6.8 ± 2.7 6.9 ± 2.7 7.4 ± 2.7 7.7 ± 2.7 7.6 ± 2.5 —h β 0.03 (−0.002; 0.06)i,†
 High (DBI ≥ 1) 6.8 ± 2.8 6.4 ± 2.7 6.9 ± 2.5 6.6 ± 2.9 7.1 ± 2.6 7.0 ± 2.4 —h β 0.07 (0.02; 0.11)i,†
Physical functioning
Walking Test
 None (DBI = 0) 7.9 ± 3.3 7.9 ± 3.6 8.9 ± 4.7 9.0 ± 4.4 8.8 ± 4.2 9.3 ± 4.2 9.6 ± 4.3 Reference
 Medium (0 < DBI < 1) 9.4 ± 4.5 9.4 ± 4.5 10.3 ± 5.1 9.7 ± 4.5 9.6 ± 4.5 10.7 ± 5.8 10.3 ± 5.0 β 0.01 (0.00; 0.02)j,†
 High (DBI ≥ 1) 9.9 ± 4.7 10.1 ± 4.9 11.6 ± 6.1 11.0 ± 5.2 11.6 ± 5.5 12.2 ± 5.5 12.6 ± 5.9 β 0.01 (0.00; 0.02)j,†
Cardigan Test
 None (DBI = 0) 12.9 ± 6.4 12.6 ± 6.4 13.0 ± 6.5 13.7 ± 8.0 13.7 ± 6.8 15.0 ± 7.8 15.9 ± 8.7 Reference
 Medium (0 < DBI < 1) 14.7 ± 7.6 14.4 ± 8.1 14.5 ± 7.8 14.3 ± 8.8 14.9 ± 7.8 15.6 ± 8.7 15.7 ± 7.4 β 0.00 (−0.01; 0.01)j,†
 High (DBI ≥ 1) 15.9 ± 8.9 15.7 ± 8.5 18.1 ± 11.2 15.8 ± 10.4 17.1 ± 8.9 16.7 ± 8.8 18.7 ± 10.1 β 0.02 (0.01; 0.04)j,†
Chair Stands Test
 None (DBI = 0) 12.4 ± 3.8 12.8 ± 3.7 13.2 ± 4.2 13.0 ± 3.8 13.3 ± 3.5 13.6 ± 3.8 14.1 ± 4.2 Reference
 Medium (0 < DBI < 1) 13.6 ± 4.0 14.3 ± 4.1 14.3 ± 4.2 14.3 ± 4.7 14.1 ± 3.3 14.4 ± 4.3 14.9 ± 4.0 β 0.27 (0.09; 0.46)k,†
 High (DBI ≥ 1) 15.1 ± 4.4 14.7 ± 4.7 15.4 ± 5.8 15.4 ± 5.1 15.5 ± 3.9 15.6 ± 3.9 16.2 ± 5.2 β 0.54 (0.22; 0.86)k,†
Balance Test
 None (DBI = 0) —h 9.7 ± 1.1 9.9 ± 0.7 9.8 ± 1.0 9.8 ± 0.7 9.8 ± 0.9 9.6 ± 1.2 Reference
 Medium (0 < DBI < 1) —h 9.6 ± 1.1 9.8 ± 0.9 9.8 ± 0.9 9.8 ± 0.8 9.8 ± 0.8 9.9 ± 0.6 OR 1.09 (0.86; 1.38)l,§
 High (DBI ≥ 1) —h 9.6 ± 1.3 9.8 ± 0.9 9.9 ± 0.6 9.8 ± 0.8 9.7 ± 1.2 9.8 ± 0.9 OR 1.27 (0.90; 1.77)l,§
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a self-reported measure of functional independence which reflects 
what people think they are able to do.
The present findings have two implications. First, in research, the 
DBI could serve as an important covariate that may be controlled for 
particularly when studying cognitive and physical aging in commu-
nity-dwelling older people (36). Second, in clinical practice, the DBI 
may be useful to identify individuals with polypharmacy who are 
at risk of cognitive and physical decline which may be medication-
induced. Given that the DBI is based on patients’ medication pre-
scriptions and does not require blood withdrawal, it is noninvasive 
and feasible for large-scale routine use (37). Associations between 
the DBI and cognitive and physical impairments remained signifi-
cant even after controlling for other causes such as comorbidities 
that were likely to increase over time. Therefore, even for patients 
with prolonged use of these medications, it may still be worthwhile 
to “deprescribe” inappropriate anticholinergic and sedative medi-
cations and to minimize doses if these medications are appropriate 
(38,39). Follow-up investigations of the DBI with regard to these 
issues are warranted.
A number of methodological issues need to be considered. 
Although strength of the LASA study is its long-term follow-up of 
20  years, a longer follow-up also increases the risk of differential 
attrition. To anticipate on this, older people and men were oversam-
pled to reduce potential differential loss-to-follow-up with regard 
to sex and age. Nevertheless, selection still occurred. However, it 
should also be noted that selective loss-to-follow-up of participants 
with these characteristics is inherent to studying an aging popula-
tion. Thus, while the largest source of attrition in the sample, that 
is, mortality, leads to an increasingly selective sample over time, it 
does not necessarily follow from this that the sample becomes less 
representative. Mortality occurs in the overall population as well 
and minor differences were previously shown between estimated 
mortality rates among participants of the LASA study and the total 
Dutch age-related population (40). As in all observational studies, 
we cannot rule out residual confounding. However, we attempted to 
minimize this by excluding participants who were potential problem 
drinkers or who had sensory deficits, conditions which are likely 
to compromise test performance. Furthermore, we adjusted for the 
number of comorbidities and the number of prescribed medications 
other than those included in the DBI. Although the LASA study is 
representative for the indigenous older Dutch population, repli-
cations in, for example, migrants would be worthwhile to pursue. 
Strength of the data from the LASA study was the measurement of 
physical functioning using both objective and subjective tests, and 
the measurement of cognitive functioning in specific areas (executive 
functioning, memory, and fluid intelligence) with tests sensitive to 
more subtle decline in addition to the MMSE as a measure of global 
cognitive functioning.
Currently, there is neither international consensus on the list of 
anticholinergic or sedative medications nor the minimal dose to use. 
There are a number of scales other than the DBI available to es-
timate cumulative exposure to anticholinergic medications, which 
may yield different results (41). Strength of the DBI compared with 
these other scales is that the DBI includes sedative medications in 
addition to anticholinergic medications and that it takes the dosages 
of medications into account. We did not have information about 
anticholinergic and sedative exposure in-between measurement oc-
casions. However, the sensitivity analysis in which we calculated a 
DBI for anticholinergic and sedative medications that had been pre-
scribed ≥1 year(s) before the measurement occasion, gave similar re-
sults as the primary analysis.
In conclusion, this longitudinal analysis of data collected over 
20 years showed that prolonged cumulative exposure to anticholin-
ergic and sedative medications was associated with poorer cognitive 
and physical functioning.
Supplementary Material
Supplementary data are available at The Journals of Gerontology, 
Series A: Biological Sciences and Medical Sciences online.
Measurement Occasions (y) (M, SD) Adjusted Parameter
Outcome × DBI 92/93 95/96 98/99 01/02 05/06 08/09 11/12 (95% CI)a
Functional independence
 None (DBI = 0) —h 21.6 ± 4.2 21.2 ± 4.6 20.7 ± 4.9 20.4 ± 5.1 20.1 ± 5.0 19.4 ± 5.3 Reference
 Medium (0 < DBI < 1) —h 19.2 ± 5.6 19.2 ± 5.4 19.3 ± 5.5 19.0 ± 5.2 18.5 ± 5.6 18.1 ± 5.6 β −0.23 (−0.50; 0.03)m,§
 High (DBI ≥ 1) —h 17.4 ± 5.9 16.7 ± 6.6 17.8 ± 5.6 15.9 ± 5.8 15.6 ± 6.2 14.7 ± 6.4 β −1.17 (−1.57; −0.76)m,§
Note: Higher parameter value indicates †: poorer functioning §: better functioning. DBI = drug burden index; CI = confidence interval; MMSE = Mini-Mental 
State Examination; AVLT = Auditory Verbal Learning Test; β = unstandardized regression coefficient; OR = odds ratio. 
aAdjusted for participants’ sex, age, years of education, marital status, BMI, depressive symptoms as measured with the Center for Epidemiologic Studies Depres-
sion (CES-D) scale, number of comorbidities, and number of non-DBI medications.
bMax. 30 points.
cln(31-MMSE score).
dEach trial lasting 1 min.
eNumber correct. 
fMaximum score achieved on three trials.
gNumber of recalled words/maximum score from learning trials and expressed as a percentage.
hNot measured on measurement occasion.
iln(13-Raven score).
jlog10(number of seconds on test).
kSeconds needed to complete test.
lSeconds dichotomized: 4–9 = 0 vs 10 = 1.
mSelf-reported functional independence.
Table 3. Continued
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